Why Science? | ICH M9 BCS Biowaivers, Solubility and Permeability

The guidance provides recommendations for classifying drug substances and supporting waivers of in-vivo bioequivalence studies for eligible immediate-release solid oral dosage forms and suspensions designed for systemic delivery.

The scientific value of m9 defines a harmonised route for certain bcs-based biowaivers appears when evidence is tied to a defined regulatory decision. The guidance provides recommendations for classifying drug substances and supporting waivers of in-vivo bioequivalence studies for eligible immediate-release solid oral dosage forms and suspensions designed for systemic delivery. Keep this boundary visible: A high-solubility substance does not automatically make every formulation eligible for a biowaiver.

A strong science note separates observation from interpretation. Recalculate the dose-to-solubility boundary for m9 defines a harmonised route for certain bcs-based biowaivers using the lowest measured solubility. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Next chapter

The official page identifies CDER and CBER and explains that bioequivalent products have comparable rate and extent of absorption within predefined limits. The May 2023 Q&A adds implementation clarification.

For fda lists m9 as final level 2 guidance from may 2021, a useful explanation shows the material, method, result and decision together. The official page identifies CDER and CBER and explains that bioequivalent products have comparable rate and extent of absorption within predefined limits. The May 2023 Q&A adds implementation clarification. Preserve this guardrail: An in-vitro permeability model needs validated performance and cannot be treated as a black box.

A strong science note separates observation from interpretation. Challenge the markers, recovery and integrity controls for fda lists m9 as final level 2 guidance from may 2021. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Class I combines high solubility and high permeability; Class II low solubility and high permeability; Class III high solubility and low permeability; and Class IV low solubility and low permeability. M9 biowaivers focus on suitable Class I and Class III situations.

A trustworthy account of the bcs contains four solubility-permeability classes keeps assumptions, uncertainty and lifecycle action in the same record. Class I combines high solubility and high permeability; Class II low solubility and high permeability; Class III high solubility and low permeability; and Class IV low solubility and low permeability. M9 biowaivers focus on suitable Class I and Class III situations. Remember: Excipient similarity matters especially when permeability, transport or gastrointestinal conditions can be affected.

A strong science note separates observation from interpretation. Compare test and reference unit-level dissolution for the bcs contains four solubility-permeability classes in every required medium. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A drug substance is highly soluble when the highest single therapeutic dose dissolves in 250 millilitres or less of aqueous media across the specified physiological pH range at about 37 degrees Celsius. The lowest measured solubility drives the classification.

The scientific value of high solubility is assessed against the highest single therapeutic dose appears when evidence is tied to a defined regulatory decision. A drug substance is highly soluble when the highest single therapeutic dose dissolves in 250 millilitres or less of aqueous media across the specified physiological pH range at about 37 degrees Celsius. The lowest measured solubility drives the classification. Keep this boundary visible: A biowaiver replaces an in-vivo study only within the scope supported by the full evidence package.

A strong science note separates observation from interpretation. Reassess high solubility is assessed against the highest single therapeutic dose after a formulation, process, strength or reference-product change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Media, pH, temperature, equilibration, solid excess, replicates, filtration, substance stability and validated assay performance are documented. Apparent solubility affected by supersaturation or degradation can misclassify the substance.

For solubility experiments need controlled equilibrium and analysis, a useful explanation shows the material, method, result and decision together. Media, pH, temperature, equilibration, solid excess, replicates, filtration, substance stability and validated assay performance are documented. Apparent solubility affected by supersaturation or degradation can misclassify the substance. Preserve this guardrail: A high-solubility substance does not automatically make every formulation eligible for a biowaiver.

A strong science note separates observation from interpretation. Recalculate the dose-to-solubility boundary for solubility experiments need controlled equilibrium and analysis using the lowest measured solubility. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A conclusion can rely on absolute bioavailability, mass-balance recovery of absorbed material or a suitably validated in-vitro permeability method such as Caco-2. M9 uses at least 85 percent absorbed as the high-permeability benchmark.

A trustworthy account of high permeability requires evidence of extensive human absorption keeps assumptions, uncertainty and lifecycle action in the same record. A conclusion can rely on absolute bioavailability, mass-balance recovery of absorbed material or a suitably validated in-vitro permeability method such as Caco-2. M9 uses at least 85 percent absorbed as the high-permeability benchmark. Remember: An in-vitro permeability model needs validated performance and cannot be treated as a black box.

A strong science note separates observation from interpretation. Challenge the markers, recovery and integrity controls for high permeability requires evidence of extensive human absorption. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Cell systems are characterised with high- and low-permeability markers, monolayer integrity and, where relevant, efflux information. Drug stability, nonspecific binding, concentration effects and recovery help distinguish true transport from an assay artefact.

The scientific value of permeability models need markers, integrity and transport controls appears when evidence is tied to a defined regulatory decision. Cell systems are characterised with high- and low-permeability markers, monolayer integrity and, where relevant, efflux information. Drug stability, nonspecific binding, concentration effects and recovery help distinguish true transport from an assay artefact. Keep this boundary visible: Excipient similarity matters especially when permeability, transport or gastrointestinal conditions can be affected.

A strong science note separates observation from interpretation. Compare test and reference unit-level dissolution for permeability models need markers, integrity and transport controls in every required medium. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The proposed product should fall within M9’s immediate-release systemic-delivery scope. Narrow therapeutic index drugs are excluded. Prodrugs, fixed-dose combinations and other situations require the guidance’s specific conditions and a clear component-by-component assessment.

For eligibility begins with the dosage form and therapeutic context, a useful explanation shows the material, method, result and decision together. The proposed product should fall within M9’s immediate-release systemic-delivery scope. Narrow therapeutic index drugs are excluded. Prodrugs, fixed-dose combinations and other situations require the guidance’s specific conditions and a clear component-by-component assessment. Preserve this guardrail: A biowaiver replaces an in-vivo study only within the scope supported by the full evidence package.

A strong science note separates observation from interpretation. Reassess eligibility begins with the dosage form and therapeutic context after a formulation, process, strength or reference-product change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

They contain the same drug substance and are evaluated at the same strength or a justified condition. Formulation, manufacturing process and product performance are reviewed because dissolution and absorption can change even when the active ingredient is identical.

A trustworthy account of the test and reference products must be pharmaceutically comparable keeps assumptions, uncertainty and lifecycle action in the same record. They contain the same drug substance and are evaluated at the same strength or a justified condition. Formulation, manufacturing process and product performance are reviewed because dissolution and absorption can change even when the active ingredient is identical. Remember: A high-solubility substance does not automatically make every formulation eligible for a biowaiver.

A strong science note separates observation from interpretation. Recalculate the dose-to-solubility boundary for the test and reference products must be pharmaceutically comparable using the lowest measured solubility. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

For Class I products, differences can be acceptable, but excipients that may affect absorption require close comparison. Class III products generally need qualitative sameness and quantitative similarity because permeability is the limiting property and excipient effects can become more influential.

The scientific value of excipients receive a risk-based similarity assessment appears when evidence is tied to a defined regulatory decision. For Class I products, differences can be acceptable, but excipients that may affect absorption require close comparison. Class III products generally need qualitative sameness and quantitative similarity because permeability is the limiting property and excipient effects can become more influential. Keep this boundary visible: An in-vitro permeability model needs validated performance and cannot be treated as a black box.

A strong science note separates observation from interpretation. Challenge the markers, recovery and integrity controls for excipients receive a risk-based similarity assessment. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Class I products can qualify when test and reference are both very rapidly dissolving, or rapidly dissolving with similar profiles, under the specified conditions. Class III products generally need very rapid dissolution in all required media.

For very rapid or rapid dissolution supports product comparison, a useful explanation shows the material, method, result and decision together. Class I products can qualify when test and reference are both very rapidly dissolving, or rapidly dissolving with similar profiles, under the specified conditions. Class III products generally need very rapid dissolution in all required media. Preserve this guardrail: Excipient similarity matters especially when permeability, transport or gastrointestinal conditions can be affected.

A strong science note separates observation from interpretation. Compare test and reference unit-level dissolution for very rapid or rapid dissolution supports product comparison in every required medium. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Compendial basket or paddle apparatus, controlled agitation, 37-degree media, pH 1.2, 4.5 and 6.8, suitable volume, at least 12 units, planned sampling and a validated assay provide a reproducible comparison. Surfactants are generally not used for the M9 comparison.

A trustworthy account of comparative dissolution uses standardised conditions keeps assumptions, uncertainty and lifecycle action in the same record. Compendial basket or paddle apparatus, controlled agitation, 37-degree media, pH 1.2, 4.5 and 6.8, suitable volume, at least 12 units, planned sampling and a validated assay provide a reproducible comparison. Surfactants are generally not used for the M9 comparison. Remember: A biowaiver replaces an in-vivo study only within the scope supported by the full evidence package.

A strong science note separates observation from interpretation. Reassess comparative dissolution uses standardised conditions after a formulation, process, strength or reference-product change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

When products dissolve rapidly rather than very rapidly, f2 can quantify profile similarity under appropriate conditions and data rules. It should not be applied mechanically when variability, sampling design or near-complete early dissolution makes the calculation unsuitable.

The scientific value of the similarity factor f2 has a defined role appears when evidence is tied to a defined regulatory decision. When products dissolve rapidly rather than very rapidly, f2 can quantify profile similarity under appropriate conditions and data rules. It should not be applied mechanically when variability, sampling design or near-complete early dissolution makes the calculation unsuitable. Keep this boundary visible: A high-solubility substance does not automatically make every formulation eligible for a biowaiver.

A strong science note separates observation from interpretation. Recalculate the dose-to-solubility boundary for the similarity factor f2 has a defined role using the lowest measured solubility. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Particle size, polymorph, salt form, granulation, compression and coating can affect dissolution. A biowaiver package explains why commercial manufacture will preserve the properties demonstrated by the submitted batches.

For manufacturing and solid-state factors remain relevant, a useful explanation shows the material, method, result and decision together. Particle size, polymorph, salt form, granulation, compression and coating can affect dissolution. A biowaiver package explains why commercial manufacture will preserve the properties demonstrated by the submitted batches. Preserve this guardrail: An in-vitro permeability model needs validated performance and cannot be treated as a black box.

A strong science note separates observation from interpretation. Challenge the markers, recovery and integrity controls for manufacturing and solid-state factors remain relevant. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Classifying a drug substance as Class I does not waive studies for every formulation. Each test product must satisfy scope, composition and dissolution criteria against the relevant reference. A new strength or formulation receives its own justified bridge.

A trustworthy account of a biowaiver decision remains product specific keeps assumptions, uncertainty and lifecycle action in the same record. Classifying a drug substance as Class I does not waive studies for every formulation. Each test product must satisfy scope, composition and dissolution criteria against the relevant reference. A new strength or formulation receives its own justified bridge. Remember: Excipient similarity matters especially when permeability, transport or gastrointestinal conditions can be affected.

A strong science note separates observation from interpretation. Compare test and reference unit-level dissolution for a biowaiver decision remains product specific in every required medium. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Protocols, raw and summary solubility data, permeability evidence, validation, excipient tables, batch information, dissolution unit data, profiles, calculations, deviations and conclusions are presented with clear traceability.

The scientific value of the dossier should let a reviewer reproduce every classification appears when evidence is tied to a defined regulatory decision. Protocols, raw and summary solubility data, permeability evidence, validation, excipient tables, batch information, dissolution unit data, profiles, calculations, deviations and conclusions are presented with clear traceability. Keep this boundary visible: A biowaiver replaces an in-vivo study only within the scope supported by the full evidence package.

A strong science note separates observation from interpretation. Reassess the dossier should let a reviewer reproduce every classification after a formulation, process, strength or reference-product change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The record includes therapeutic dose, pH range, solubility method, absorption or permeability evidence, BCS class, eligibility and exclusion checks, test and reference composition, absorption-relevant excipients, manufacturing information, dissolution methods, unit results, f2 where used, Q&A interpretations and final justification.

For a complete m9 receipt preserves the boundary of the waiver, a useful explanation shows the material, method, result and decision together. The record includes therapeutic dose, pH range, solubility method, absorption or permeability evidence, BCS class, eligibility and exclusion checks, test and reference composition, absorption-relevant excipients, manufacturing information, dissolution methods, unit results, f2 where used, Q&A interpretations and final justification. Preserve this guardrail: A high-solubility substance does not automatically make every formulation eligible for a biowaiver.

A strong science note separates observation from interpretation. Recalculate the dose-to-solubility boundary for a complete m9 receipt preserves the boundary of the waiver using the lowest measured solubility. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter